Retatrutide's Phase 3, and the Gray Market

A phase 3 trial of retatrutide — a single molecule that hits three receptors instead of one or two — reported HbA1c down 1.94 points and weight down 15.3% at 40 weeks on its top dose.^[1] It is a real result from a real trial. It is also a result for a drug you cannot legally be prescribed, and the eleven sellers in our register already shipping something called retatrutide are not selling what was studied.

What was tested

TRANSCEND-T2D-1 enrolled 537 adults across 48 sites in the United States, Mexico and India, all of whom had type 2 diabetes that diet and exercise alone were not controlling, an HbA1c between 7.0% and 9.5%, and a BMI of at least 23. They were assigned in equal quarters to weekly injections of retatrutide at 4, 9 or 12 mg, or to placebo, for 40 weeks. The question was HbA1c; weight was a secondary endpoint.

Every dose beat placebo at p<0.0001, tolerability was unremarkable for the class — gut effects that faded, discontinuations of 2% to 5% against 0% on placebo — and no severe hypoglycemia occurred. Two deaths were recorded, both in the 4 mg arm, both judged unrelated.

Read the population before reading the numbers

That is not a criticism of the trial — monotherapy in drug-naive patients is a legitimate and necessary question, and it is what the trial says it studied. It is a caution against reading these numbers as what retatrutide would do for someone ten years into diabetes on three medications.

The other framing worth resisting: 40 weeks is shorter than the 68- and 72-week obesity trials most readers have in their heads, and weight here was secondary to blood sugar. A 15.3% figure at 40 weeks in a diabetes trial is not the same object as a percentage from a dedicated obesity trial run half again as long, and we are not going to set them side by side.

The part that concerns this register

Retatrutide is not approved for any use, in any country. It has no FDA label, no prescribing information, no approved manufacturer, and no legal pathway to a pharmacy. A good phase 3 result does not change any of that, and it does something worse in the short term: it raises demand for a drug the legitimate supply chain cannot fill.

The trial and the vial are different objects. A published result tells you nothing about what is in an unlabeled bottle.

In the trial, participants received material manufactured to clinical-trial standard, at a verified concentration, with a known impurity profile, injected on a schedule supervised by a study team. None of those properties transfer to a vial bought online, and every one of them is load-bearing for the result above. A powder sold as retatrutide has no independent verification of identity, purity, concentration, sterility or stability, because there is no approved product to verify it against.

We track sellers offering it because a reader deserves to know before they order, not after. The register’s standing coverage is in retatrutide: what the evidence shows, and the pattern of research-chemical marketing generally is in research chemical listings.

What would change this

• An FDA approval, which brings a label, a manufacturer of record, and a defined dose and schedule.
• Cardiovascular and kidney outcome data. Blood sugar and weight are intermediate endpoints. Glucagon receptor agonism is a genuinely new element in this class, and what it does to hard outcomes over years is unestablished.
• Longer trials. Forty weeks is a snapshot for a drug intended to be taken indefinitely.
• Data in harder populations — longer diabetes duration, existing therapy, older patients.

Until then the honest summary is short: the science is promising, the drug is unapproved, and what is for sale is not the drug in the trial.